BR112014013820A2 - distribuição lipídica eficiente a um filme lacrimal humano usando um sistema de emulsão sensível ao sal - Google Patents

distribuição lipídica eficiente a um filme lacrimal humano usando um sistema de emulsão sensível ao sal

Info

Publication number
BR112014013820A2
BR112014013820A2 BR112014013820A BR112014013820A BR112014013820A2 BR 112014013820 A2 BR112014013820 A2 BR 112014013820A2 BR 112014013820 A BR112014013820 A BR 112014013820A BR 112014013820 A BR112014013820 A BR 112014013820A BR 112014013820 A2 BR112014013820 A2 BR 112014013820A2
Authority
BR
Brazil
Prior art keywords
salt
tear film
sensitive emulsion
human tear
emulsion system
Prior art date
Application number
BR112014013820A
Other languages
English (en)
Other versions
BR112014013820A8 (pt
Inventor
G Vehige Joseph
A Simmons Peter
Original Assignee
Allergan Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47459152&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR112014013820(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Allergan Inc filed Critical Allergan Inc
Publication of BR112014013820A8 publication Critical patent/BR112014013820A8/pt
Publication of BR112014013820A2 publication Critical patent/BR112014013820A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/047—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates having two or more hydroxy groups, e.g. sorbitol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/341—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide not condensed with another ring, e.g. ranitidine, furosemide, bufetolol, muscarine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/716—Glucans
    • A61K31/717—Celluloses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/04—Artificial tears; Irrigation solutions

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • Ophthalmology & Optometry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dispersion Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

abstract a salt-free emulsion for the treatment of dry eye and other ocular conditions is disclosed which contains castor oil and does not contain olive oil which prolongs tbut and provides superior comfort. ______________________________________________________________ tradução resumo patente de invenção: "distribuição lipídica eficiente a um filme lacrimal humano usando um sistema de emulsão sensível ao sal". é descrita uma emulsão isenta de sal para o tratamento de olho seco e outras doenças oculares a qual contém óleo de rícino e não contém óleo de oliva, a qual prolonga o tbut e confere maior conforto.
BR112014013820A 2011-12-07 2012-12-07 distribuição lipídica eficiente a um filme lacrimal humano usando um sistema de emulsão sensível ao sal BR112014013820A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161568089P 2011-12-07 2011-12-07
US201261625401P 2012-04-17 2012-04-17
PCT/US2012/068615 WO2013086449A1 (en) 2011-12-07 2012-12-07 Efficient lipid delivery to human tear film using a salt-sensitive emulsion system

Publications (2)

Publication Number Publication Date
BR112014013820A8 BR112014013820A8 (pt) 2017-06-13
BR112014013820A2 true BR112014013820A2 (pt) 2017-06-13

Family

ID=47459152

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112014013820A BR112014013820A2 (pt) 2011-12-07 2012-12-07 distribuição lipídica eficiente a um filme lacrimal humano usando um sistema de emulsão sensível ao sal

Country Status (28)

Country Link
US (2) US20130150324A1 (pt)
EP (5) EP2787968B1 (pt)
JP (1) JP6142419B2 (pt)
KR (1) KR102017922B1 (pt)
CN (2) CN108969482A (pt)
AR (1) AR089123A1 (pt)
AU (2) AU2012347459A1 (pt)
BR (1) BR112014013820A2 (pt)
CA (1) CA2858574C (pt)
CL (1) CL2014001518A1 (pt)
CO (1) CO6990739A2 (pt)
DK (2) DK2787969T3 (pt)
ES (2) ES2896336T3 (pt)
HK (2) HK1201458A1 (pt)
HU (2) HUE057140T2 (pt)
IL (1) IL233008A (pt)
IN (1) IN2014CN04809A (pt)
MX (1) MX355216B (pt)
MY (1) MY173378A (pt)
PH (1) PH12014501296A1 (pt)
PL (2) PL2787969T3 (pt)
PT (2) PT2787969T (pt)
RU (1) RU2014127074A (pt)
SG (1) SG11201403013VA (pt)
SI (2) SI2787969T1 (pt)
TW (1) TWI652072B (pt)
WO (2) WO2013086449A1 (pt)
ZA (1) ZA201404228B (pt)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8957048B2 (en) * 2011-10-06 2015-02-17 Allergan, Inc. Compositions for the treatment of dry eye
US9907826B2 (en) 2011-12-07 2018-03-06 Allergan, Inc. Efficient lipid delivery to human tear film using a salt-sensitive emulsion system
PL3266446T3 (pl) 2016-07-07 2019-05-31 Salvat Lab Sa Kompozycja oftalmiczna zawierająca olej rycynowy i trójgliceryd o średniej długości łańcucha
WO2018035469A1 (en) 2016-08-19 2018-02-22 Akrivista, LLC Methods of diagnosing and treating dry eye syndrome and compositions for treating a human eye
CN111295169A (zh) 2017-08-18 2020-06-16 阿克里维斯塔有限责任公司 诊断和治疗干眼综合症的方法和用于治疗人类眼睛的组合物
CA3097998A1 (en) 2018-04-27 2019-10-31 Allergan, Inc. Sodium chlorite compositions with enhanced anti-microbial efficacy and reduced toxicity

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4201706A (en) 1978-09-22 1980-05-06 Burton, Parsons & Company, Inc. Treatment of corneal edema
ATE6466T1 (de) * 1979-10-26 1984-03-15 Smith And Nephew Associated Companies P.L.C. Autoklavierbare emulsionen.
US5192535A (en) 1988-02-08 1993-03-09 Insite Vision Incorporated Ophthalmic suspensions
IT1224795B (it) 1988-12-01 1990-10-24 Sigma Tau Ind Farmaceuti Uso dell'acetil d-carnitina nel trattamento terapeutico del glaucoma e composizioni farmaceutiche utili in tale trattamento
WO1991001718A1 (fr) 1989-08-03 1991-02-21 Eisai Co., Ltd. Procede de photostabilisation pour collyre liquide et collyre liquide photostabilise
US5681555A (en) 1991-04-22 1997-10-28 Gleich; Gerald J. Method for the treatment of bronchial asthma by parenteral administration of anionic polymers
DE4229494A1 (de) 1992-09-04 1994-03-10 Basotherm Gmbh Arzneimittel zur topischen Anwendung am Auge zur Behandlung des erhöhten intraokularen Drucks
AU3484895A (en) 1994-09-14 1996-03-29 Taisho Pharmaceutical Co., Ltd. Eye drops for repairing corneal disturbance
US5980865A (en) 1995-08-18 1999-11-09 Baker Norton Pharmaceuticals, Inc. Method for treating late phase allergic reactions and inflammatory diseases
FI106923B (fi) 1997-01-03 2001-05-15 Cultor Ltd Finnsugar Bioproduc Trimetyyliglysiinin käyttö kehon limakalvojen hygieniaan ja hoitoon tarkoitetuissa valmisteissa
AR002194A1 (es) 1997-03-17 1998-01-07 Sanchez Reynaldo Alemany Instrumento computarizado para el analisis del movimiento.
IT1302307B1 (it) 1998-09-01 2000-09-05 Sigma Tau Healthscience Spa Composizione ad attivita' antiossidante ed atta a migliorarel'utilizzazione metabolica del glucosio, comprendente acetil
WO2000029030A1 (en) 1998-11-13 2000-05-25 Continental Projects Limited Complexes of hyaluronic acid/carnitines and pharmaceutical and cosmetic compositions
JP2000159659A (ja) * 1998-11-30 2000-06-13 Kazuo Tsubota 眼科用人工涙液
US6228392B1 (en) 1999-04-29 2001-05-08 Gene Tools, Llc Osmotic delivery composition, solution, and method
MXPA02012206A (es) 2000-07-14 2003-06-04 Allergan Inc Composiciones que contienen componentes terapeuticamente activos que tienen solubilidad mejorada.
CA2355814C (en) 2000-09-14 2010-06-29 Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo Pharmaceutical composition for ophthalmic use
JP4084997B2 (ja) 2000-11-08 2008-04-30 エフエックスエス・ベンチャーズ・エルエルシー 防腐剤増強剤として単純糖類を含有する改良眼科用およびコンタクトレンズ用溶液
US7045121B2 (en) 2001-12-14 2006-05-16 Allergan, Inc. Ophthalmic compositions for lubricating eyes and methods for making and using same
WO2004028536A1 (en) 2002-09-30 2004-04-08 Babizhayev Mark A Method for topical treatment of eye disease and composition and device for said treatment
WO2004035005A2 (en) * 2002-10-18 2004-04-29 Echols Joel S Three layer tear formulation
US20040137079A1 (en) 2003-01-08 2004-07-15 Cook James N. Contact lens and eye drop rewetter compositions and methods
US6635654B1 (en) * 2003-01-09 2003-10-21 Allergan, Inc. Ophthalmic compositions containing loratadine
WO2004084877A1 (ja) 2003-03-26 2004-10-07 Menicon Co., Ltd. 眼科用組成物
CA2527712C (en) * 2003-06-13 2014-08-05 Alcon, Inc. Ophthalmic compositions containing a synergistic combination of two polymers
TWI336257B (en) * 2003-06-13 2011-01-21 Alcon Inc Ophthalmic compositions containing a synergistic combination of three polymers
US20050009836A1 (en) 2003-06-26 2005-01-13 Laskar Paul A. Ophthalmic composition containing quinolones and method of use
KR20060121151A (ko) * 2003-11-10 2006-11-28 도레이 가부시끼가이샤 다당류 함유 조성물 및 누액층 안정화 점안제
US8569367B2 (en) 2004-11-16 2013-10-29 Allergan, Inc. Ophthalmic compositions and methods for treating eyes
US7288520B2 (en) * 2005-07-13 2007-10-30 Allergan, Inc. Cyclosporin compositions
US9561178B2 (en) * 2006-07-25 2017-02-07 Allergan, Inc. Cyclosporin compositions
WO2008035246A2 (en) * 2006-07-28 2008-03-27 Novagali Pharma Sa Compositions containing quaternary ammonium compounds
CN101896160A (zh) * 2006-10-17 2010-11-24 阿勒根公司 环胞菌素组合物
EP2131809A2 (en) * 2007-02-28 2009-12-16 Aciex Therapeutics, Inc. Methods and compositions for normalizing meibomian gland secretions
JP4929245B2 (ja) 2008-07-31 2012-05-09 株式会社ベッセル工業 工具類のグリップ
CN102458430A (zh) * 2009-06-05 2012-05-16 阿勒根公司 人工泪液及治疗用途
US8957048B2 (en) * 2011-10-06 2015-02-17 Allergan, Inc. Compositions for the treatment of dry eye

Also Published As

Publication number Publication date
ZA201404228B (en) 2015-12-23
CN108969482A (zh) 2018-12-11
BR112014013820A8 (pt) 2017-06-13
AR089123A1 (es) 2014-07-30
WO2013086438A1 (en) 2013-06-13
EP2787969B1 (en) 2021-09-29
US20130197083A1 (en) 2013-08-01
MX2014006804A (es) 2014-09-22
CN104114152A (zh) 2014-10-22
MX355216B (es) 2018-04-10
CA2858574A1 (en) 2013-06-13
HUE049489T2 (hu) 2020-09-28
SI2787969T1 (sl) 2021-12-31
RU2018119362A3 (pt) 2021-09-07
DK2787968T3 (da) 2020-06-02
EP2787968B1 (en) 2020-03-04
RU2014127074A (ru) 2016-02-10
KR20140107383A (ko) 2014-09-04
DK2787969T3 (da) 2021-11-01
CL2014001518A1 (es) 2014-10-24
AU2017265181A1 (en) 2017-12-14
SG11201403013VA (en) 2014-07-30
EP3981387A1 (en) 2022-04-13
EP3666257A1 (en) 2020-06-17
JP6142419B2 (ja) 2017-06-07
AU2017265181B2 (en) 2019-06-20
PT2787969T (pt) 2021-11-09
WO2013086449A1 (en) 2013-06-13
KR102017922B1 (ko) 2019-09-03
CA2858574C (en) 2017-05-30
EP4403220A2 (en) 2024-07-24
US20130150324A1 (en) 2013-06-13
PL2787968T3 (pl) 2020-08-24
PT2787968T (pt) 2020-06-16
HUE057140T2 (hu) 2022-04-28
MY173378A (en) 2020-01-21
JP2015504860A (ja) 2015-02-16
PL2787969T3 (pl) 2021-12-20
IL233008A0 (en) 2014-07-31
ES2797650T3 (es) 2020-12-03
TW201325633A (zh) 2013-07-01
ES2896336T3 (es) 2022-02-24
IN2014CN04809A (pt) 2015-09-18
PH12014501296A1 (en) 2014-10-08
HK1201458A1 (en) 2015-09-04
RU2018119362A (ru) 2018-11-08
EP2787969A1 (en) 2014-10-15
EP2787968A1 (en) 2014-10-15
US9314528B2 (en) 2016-04-19
SI2787968T1 (sl) 2020-08-31
CO6990739A2 (es) 2014-07-10
IL233008A (en) 2017-07-31
TWI652072B (zh) 2019-03-01
HK1203057A1 (en) 2015-10-16
AU2012347459A1 (en) 2014-07-03

Similar Documents

Publication Publication Date Title
BR112014013820A8 (pt) distribuição lipídica eficiente a um filme lacrimal humano usando um sistema de emulsão sensível ao sal
BR112015001847A2 (pt) composições e tratamento para doenças e distúrbios nos olhos
EA201792559A1 (ru) Фармацевтические композиции для местного применения
BR112014008789A2 (pt) prevenção e tratamento de condições oculares
BR112014014378A2 (pt) composição e uso da mesma para tratar doença ocular relacionada a ácido nucleico
EA201590655A1 (ru) Комбинация лахинимода и придопидина для лечения нейродегенеративных нарушений
BR112012027543A8 (pt) formulações de quinonas para tratamento de doenças oftálmicas
BR112014010376A2 (pt) medicamento para o tratamento de doença do olho anterior que compreende rebamipida e um agente de retenção de lágrima
EA201590654A1 (ru) Комбинация разагилина и придопидина для лечения нейродегенеративных нарушений, в частности болезни хантингтона
EA201490163A1 (ru) Ингибиторы кинуренин-3-монооксигеназы, фармацевтические композиции и способы их применения
BR112013005438A2 (pt) "agente para o tratamento de olho ressecado caracterizado por combinar o agonista do receptor de p2y2 e ácido hialurônico ou um sal do mesmo, método para o tratamento de olho ressecado, e uso do agonista do receptor de p2y2, e ácido hialurônico ou um sal do mesmo."
BR112013017745A2 (pt) métodos para o diagnóstico e tratamento de distúrbios relacionados ao comprimento do olho
EA201491606A1 (ru) Ингибиторы кинуренин-3-монооксигеназы, фармацевтические композиции и способы их применения
BR112014001118A2 (pt) combinação tópica para aplicação oftálmica e uso de bimatoprost e brimonidina
TN2010000251A1 (fr) N-acetyl-dl-leucine medicament neuro et retino protecteur
EA201692402A1 (ru) Лекарственные формы для местного применения и их использование
BR112015027631A2 (pt) Métodos para melhorar perfis de lipídeo usando atrasentana
CY1120642T1 (el) Φαρμακευτικη συνθεση της ιβουπροφαιμνης και της τραμαδολης για οφθαλμολογικη χρηση
NZ607103A (en) A water-in-oil type emulsion for treating a disease of the eye
EA201691656A2 (ru) Терапевтические способы с применением норибогаина и родственных соединений
CY1124538T1 (el) Χρηση prg4 για τη βελτιωση της δυναμικης οπτικης οξυτητας και εκτροπων υψηλοτερης ταξης
EA201600469A1 (ru) Фармацевтический препарат для профилактики и лечения прогрессирующей близорукости
MA56220A (fr) Formulations oculaires permettant l'administration de médicament et la protection du segment antérieur de l'oeil
CL2020001426A1 (es) Composición tópica oftálmica que comprende ácido dobesilico para tratar enfermedades del segmento posterior del ojo.
BR112014011336A2 (pt) composições farmacêuticas que compreendem 7-(1h-imidazol-4-ilmetil)-5,6,7,8-tetra-hidro-quinolina para tratamento de doenças e condições de pele

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B350 Update of information on the portal [chapter 15.35 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B154 Notification of filing of divisional application [chapter 15.50 patent gazette]

Free format text: O PEDIDO FOI DIVIDIDO NO BR122023012226-7 PROTOCOLO 870230052581 EM 19/06/2023 18:31.

B09B Patent application refused [chapter 9.2 patent gazette]
B12B Appeal against refusal [chapter 12.2 patent gazette]